Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPC3-CAR-ORI2 T cells
- Development stage
- Unknown
- Lead developer
- OriCell Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GPC3-CAR-ORI2 T cells are an autologous chimeric antigen receptor (CAR) T cell therapy engineered to target glypican 3 (GPC3), a cell surface protein highly expressed in hepatocellular carcinoma (HCC) and other solid tumors. This "armored" second-generation CAR-T incorporates a proprietary Ori2 element following the 4-1BB and CD3ζ signaling domains, designed to enhance memory stem cell ratio, proliferation, persistence, and antitumor activity compared to traditional CAR-T therapies. Preclinical studies demonstrated improved efficacy both in vitro and in vivo. The product is being evaluated primarily for relapsed or refractory HCC but may have potential for other GPC3-positive solid tumors[1][4].
- Other names
- Anti-GPC3 CAR T-cell therapy (OriginCell)gpc3-car-ori2gpc-3-car-ori2gpc 3-car-ori2G3-CAR-Ori2G-3-CAR-Ori2G 3-CAR-Ori2
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on GPC3-CAR-ORI2 T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPC3-CAR-ORI2 T cells.